Cargando…

New variants of alpha-1-antitrypsin: structural simulations and clinical expression

BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is characterized by reduced serum levels of the AAT protein and predisposes to liver and lung disease. The characterization at structural level of novel pathogenic SERPINA1 mutants coding for circulating AAT could provide novel insights into the mech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez, Angel, Belmonte, Irene, Nuñez, Alexa, Farago, Georgina, Barrecheguren, Miriam, Pons, Mònica, Orriols, Gerard, Gabriel-Medina, Pablo, Rodríguez-Frías, Francisco, Miravitlles, Marc, Esquinas, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741788/ https://www.ncbi.nlm.nih.gov/pubmed/36496391 http://dx.doi.org/10.1186/s12931-022-02271-8

Ejemplares similares

Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
por: Núñez, Alexa, et al.
Publicado: (2021)

Correction to: Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
por: Núñez, Alexa, et al.
Publicado: (2021)

Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory
por: Belmonte, Irene, et al.
Publicado: (2020)

Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency
por: Pons, Mònica, et al.
Publicado: (2021)

Application of a diagnostic algorithm for the rare deficient variant Mmalton of alpha-1-antitrypsin deficiency: a new approach
por: Belmonte, Irene, et al.
Publicado: (2016)

Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency
por: Esquinas, Cristina, et al.
Publicado: (2017)

Diagnosis of alpha-1 antitrypsin deficiency: a population-based study
por: Barrecheguren, Miriam, et al.
Publicado: (2016)

Practice and knowledge about diagnosis and treatment of alpha-1 antitrypsin deficiency in Spain and Portugal
por: Esquinas, Cristina, et al.
Publicado: (2016)

Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT)
por: Esquinas, Cristina, et al.
Publicado: (2018)

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency
por: Greulich, Timm, et al.
Publicado: (2018)

Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire
por: Núñez, Alexa, et al.
Publicado: (2018)

Alpha-1 antitrypsin deficiency: outstanding questions and future directions
por: Torres-Durán, María, et al.
Publicado: (2018)

New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2020)

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2022)

Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update
por: Blanco, Ignacio, et al.
Publicado: (2017)

Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide
por: Blanco, Ignacio, et al.
Publicado: (2017)

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2023)

Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin
por: Torres-Durán, María, et al.
Publicado: (2023)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study
por: Calle Rubio, Myriam, et al.
Publicado: (2018)

Demographic and clinical characteristics of patients with α(1)-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO
por: Torres-Durán, María, et al.
Publicado: (2022)

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

Correction: Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study
por: Calle Rubio, Myriam, et al.
Publicado: (2019)

Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency
por: Lara, Beatriz, et al.
Publicado: (2007)

Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD
por: Monteagudo, Mònica, et al.
Publicado: (2021)

Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain
por: Barrecheguren, Miriam, et al.
Publicado: (2022)

Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care
por: Barrecheguren, Miriam, et al.
Publicado: (2018)

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

Long-Term Risk of Mortality Associated with Isolation of Pseudomonas aeruginosa in COPD: A Systematic Review and Meta-Analysis
por: Martinez-García, Miguel Angel, et al.
Publicado: (2022)

Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil
por: Jardim, José R, et al.
Publicado: (2021)

Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence
por: Rahaghi, Franck F., et al.
Publicado: (2017)

COPD heterogeneity: implications for management
por: Barrecheguren, Miriam, et al.
Publicado: (2016)

Association Between Routine Blood Biomarkers and Clinical Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Disease
por: Nuñez, Alexa, et al.
Publicado: (2020)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Estimated Prevalence and Number of PiMZ Genotypes of Alpha-1 Antitrypsin in Seventy-Four Countries Worldwide
por: Martinez-González, Cristina, et al.
Publicado: (2021)

Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis
por: Barjaktarevic, Igor, et al.
Publicado: (2021)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

Is SARS-COV-2 associated with alpha-1 antitrypsin deficiency?
por: Rodríguez-García, Carlota, et al.
Publicado: (2023)

Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews
por: Miravitlles, Marc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q2komej3s5da6nvsqspac05lqd